Wise R, Honeybourne D, Andrews J M, Ashby J P
Department of Medical Microbiology, Dudley Road Hospital, Birmingham, UK.
J Antimicrob Chemother. 1988 Aug;22(2):203-6. doi: 10.1093/jac/22.2.203.
Twenty patients undergoing fibreoptic endoscopy received 400 mg of fleroxacin once a day for four days. Bronchial biopsies were performed 2.7-5.9 h following the final dose of fleroxacin. A microbiological assay was used to determine the levels of fleroxacin in serum and biopsy material. The serum levels of fleroxacin ranged from 3.9-12.5 mg/l (mean 8.4, S.D. 2.4). In all but one patient the bronchial mucosa level exceeded that in serum, the range being 5.9-19 mg/l (mean 12.8, S.D. 3.3). The mean percentage penetration into bronchial mucosa over the period of the study was 158% (S.D. 41.2%). The therapeutic implications are discussed.
20名接受纤维内镜检查的患者每天服用400毫克氟罗沙星，共服用四天。在最后一剂氟罗沙星服用后2.7 - 5.9小时进行支气管活检。采用微生物测定法测定血清和活检材料中氟罗沙星的水平。氟罗沙星的血清水平范围为3.9 - 12.5毫克/升（平均8.4，标准差2.4）。除一名患者外，所有患者的支气管黏膜水平均超过血清水平，范围为5.9 - 19毫克/升（平均12.8，标准差3.3）。在研究期间，氟罗沙星进入支气管黏膜的平均百分比为158%（标准差41.2%）。文中讨论了其治疗意义。
